In the CTD/RG3 co-treated HCC allograft model, the combination regimen demonstrated significant hepatoprotective activity, as evidenced by substantial reductions in CTD-induced elevation of ALT and AST levels compared to CTD monotherapy (Fig. 7A, B). The gene discussed is GPT; the disease is hepatocellular carcinoma.